These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18685674)

  • 1. Neuroscience: Standard model.
    Schnabel J
    Nature; 2008 Aug; 454(7205):682-5. PubMed ID: 18685674
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical research: Make mouse studies work.
    Perrin S
    Nature; 2014 Mar; 507(7493):423-5. PubMed ID: 24678540
    [No Abstract]   [Full Text] [Related]  

  • 3. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

  • 4. High throughput drug screening.
    Heemskerk J
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():19-21. PubMed ID: 15512863
    [No Abstract]   [Full Text] [Related]  

  • 5. Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?
    Butsch PO; Cudkowicz ME
    Exp Neurol; 2007 Jul; 206(1):11-5. PubMed ID: 17498699
    [No Abstract]   [Full Text] [Related]  

  • 6. Lost in translation: treatment trials in the SOD1 mouse and in human ALS.
    Benatar M
    Neurobiol Dis; 2007 Apr; 26(1):1-13. PubMed ID: 17300945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of disease duration of amyotrophic lateral sclerosis in a mouse model by transgenic small interfering RNA.
    Yokota T; Sasaguri H; Saito Y; Yamada H; Unno T; Yamamoto Y; Kubodera T; Anzai M; Mitani T; Mizusawa H
    Arch Neurol; 2007 Jan; 64(1):145-6. PubMed ID: 17210827
    [No Abstract]   [Full Text] [Related]  

  • 8. Minocycline for patients with ALS.
    Carrì MT
    Lancet Neurol; 2008 Feb; 7(2):118-9; author reply 120-1. PubMed ID: 18207105
    [No Abstract]   [Full Text] [Related]  

  • 9. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.
    Ludolph AC; Bendotti C; Blaugrund E; Hengerer B; Löffler JP; Martin J; Meininger V; Meyer T; Moussaoui S; Robberecht W; Scott S; Silani V; Van Den Berg LH;
    Amyotroph Lateral Scler; 2007 Aug; 8(4):217-23. PubMed ID: 17653919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex genetics of amyotrophic lateral sclerosis.
    Kunst CB
    Am J Hum Genet; 2004 Dec; 75(6):933-47. PubMed ID: 15478096
    [No Abstract]   [Full Text] [Related]  

  • 11. A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies.
    Yamamoto M; Tanaka F; Tatsumi H; Sobue G
    Expert Opin Pharmacother; 2008 Aug; 9(11):1845-57. PubMed ID: 18627324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI detects early hindlimb muscle atrophy in Gly93Ala superoxide dismutase-1 (G93A SOD1) transgenic mice, an animal model of familial amyotrophic lateral sclerosis.
    Brooks KJ; Hill MD; Hockings PD; Reid DG
    NMR Biomed; 2004 Feb; 17(1):28-32. PubMed ID: 15011248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Has gene therapy for ALS arrived?
    Miller TM; Cleveland DW
    Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
    [No Abstract]   [Full Text] [Related]  

  • 14. From Dish to Bedside: Lessons Learned While Translating Findings from a Stem Cell Model of Disease to a Clinical Trial.
    McNeish J; Gardner JP; Wainger BJ; Woolf CJ; Eggan K
    Cell Stem Cell; 2015 Jul; 17(1):8-10. PubMed ID: 26140603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS.
    Zheng C; Nennesmo I; Fadeel B; Henter JI
    Ann Neurol; 2004 Oct; 56(4):564-7. PubMed ID: 15389897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyotrophic lateral sclerosis: pathogenesis.
    Robberecht W; Van Den Bosch L; Vleminckx V
    Acta Neurol Belg; 2000 Sep; 100(3):181-7. PubMed ID: 11098292
    [No Abstract]   [Full Text] [Related]  

  • 17. ALS predisposition modifiers: knock NOX, who's there? SOD1 mice still are.
    Valdmanis PN; Kabashi E; Dion PA; Rouleau GA
    Eur J Hum Genet; 2008 Feb; 16(2):140-2. PubMed ID: 18043718
    [No Abstract]   [Full Text] [Related]  

  • 18. Amyotrophic lateral sclerosis and gene therapy.
    Miller TM; Smith RA; Cleveland DW
    Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 20. ALS: life and death in a bad neighborhood.
    Monk PN; Shaw PJ
    Nat Med; 2006 Aug; 12(8):885-7. PubMed ID: 16892030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.